Denmark· DK-28106272419
Xenleta
A lefamulin product containing lefamulin, registered in Denmark by Nabriva Therapeutics Ireland DAC. The same ATC class is registered in 9 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Lefamulin is registered in 9 of 19 countries.
Countries holding a registration under ATC J01XX12 (lefamulin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 6 of them publish a price we can compare per daily dose
Lefamulin · ATC J01XX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Lefamulin
- Manufacturer
- Nabriva Therapeutics Ireland DAC
- Country
- Denmark (DK)
- ATC code
- J01XX12
- ATC class
- Lefamulin
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106272419
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
362 interactions on record for lefamulin.
Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lefamulin · interactions on record
362 records
- 133 severe
- 227 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01XX12
Lefamulin, as other registers publish it.
- PolandXenletaNabriva Therapeutics Ireland DAC
- IcelandXenletaVENIPHARM
- DenmarkXenletaNabriva Therapeutics Ireland DAC
- United StatesXenletaMeitheal Pharmaceuticals Inc.
- PolandXenletaNabriva Therapeutics Ireland DAC
- United StatesXenletaMeitheal Pharmaceuticals Inc.
- FinlandXenletaVenipharm
- IcelandXenletaVENIPHARM
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dac68586-0a8b-4168-b07c-1bb523eb2456 GET /v1/drugs/dac68586-0a8b-4168-b07c-1bb523eb2456?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "600 mg",
"auth_role": "MOD",
"dk_drugid": "28106272419",
"substance": "Lefamulin",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "44039"
}See everything about lefamulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.